Fibromyalgia (FM) is a common chronic pain syndrome with symptoms that include widespread pain, fatigue, sleep disruption and cognitive impairment. It is known that infections and other types of stressors are capable of triggering the development of FM. Researchers have hypothesised that these stressors could be responsible for triggering a reactivation of latent herpesviruses, and that this reactivation could, in turn, lead to the central nervous system dysregulation seen in this condition.

I have discussed central nervous system dysregulation and the vagus nerve in the article above.

The present study was designed to evaluate an anti-viral drug combination selected for activity against herpes class viruses. There continues to be research into all aspects of this condition.

The researchers combined 2 drugs which are already in use. Called MC-1, this is a fixed-dose combination using proprietary doses of famciclovir, an anti-viral nucleoside analogue, and celecoxib,
a COX-2 inhibitor that also possesses unique anti-viral activity.

A significant decrease in pain was observed in patients on treatment 33% reported a significant change is the Patient Global Impression of Change score.

Fatigue improved and the side effects were minimal.

A definitive study begins in 2017 with results by 2019. Until then this idea must remain that, just an idea.

To read more about fibromyalgia visit our Library of articles

You can read the research here.